---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-002072"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2026-01-26T23:59:59+00:00"
generated_at: "2026-05-16T08:03:18.654474+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Contineum Therapeutics approves 2026 Inducement Plan with 750,000 share reserve

## Summary
- Board approved 2026 Employment Inducement Equity Incentive Plan on January 23, 2026.
- Plan reserves 750,000 shares of Class A common stock for awards to new employees as inducement material.
- Adopted without stockholder approval under Nasdaq Rule 5635(c)(4); no incentive stock options allowed.
- Substantially similar to existing 2024 Equity Incentive Plan except for ISO prohibition and eligible recipients.

## SEC filing metadata
- accession: 0001437749-26-002072
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2026-01-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000143774926002072/0001437749-26-002072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000143774926002072/ctnm20260121_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-002072
- JSON: https://secwatch.observer/filing/0001437749-26-002072.json
- Plain text: https://secwatch.observer/filing/0001437749-26-002072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.